Privately-held gene editing company Verve Therapeutics has been cleared by the US regulator to go ahead with what will be the first in-human base editing study 26 October 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.